Steris PLC (STE)

NYSE: STE · IEX Real-Time Price · USD
207.89
+5.45 (2.69%)
Jun 24, 2022 4:00 PM EDT - Market closed
2.69%
Market Cap 20.81B
Revenue (ttm) 4.59B
Net Income (ttm) 243.89M
Shares Out 100.08M
EPS (ttm) 2.48
PE Ratio 83.83
Forward PE 20.88
Dividend $1.72 (0.83%)
Ex-Dividend Date Jun 13, 2022
Volume 790,429
Open 204.41
Previous Close 202.44
Day's Range 203.11 - 207.99
52-Week Range 192.40 - 255.93
Beta 0.66
Analysts Buy
Price Target 269.08 (+29.4%)
Earnings Date Aug 8, 2022

About STE

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in th... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jun 1, 1992
CEO Walter Rosebrough
Employees 16,000
Stock Exchange NYSE
Ticker Symbol STE
Full Company Profile

Financial Performance

In 2021, Steris's revenue was $4.59 billion, an increase of 47.55% compared to the previous year's $3.11 billion. Earnings were $243.89 million, a decrease of -38.63%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for STE stock is "Buy." The 12-month stock price forecast is 269.08, which is an increase of 29.43% from the latest price.

Price Target
$269.08
(29.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

3 Unstoppable Stocks That Are Higher Than Before the Market Correction

Market downturns don't affect stocks equally.

Other symbols: AZNSNY

Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio

Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.

STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

STERIS Announces Financial Results for Fiscal 2022 Fourth Quarter and Full Year

DUBLIN, IRELAND, May 11, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 fourth quarter ended March 31, 2022. Revenue a...

STERIS Declares $0.43 per share Dividend

DUBLIN, IRELAND , May 04, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.43 per share. T...

STERIS to Host a Conference Call for Fiscal 2022 Fourth Quarter and Full Year Financial Results on May 12, 2022

DUBLIN, IRELAND, April 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 fourth quarter and f...

This Is the Perfect Healthcare Stock to Buy and Hold for Decades

It isn't going to be facing disruption anytime soon.

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.

Other symbols: ABMDALC

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Here's Why You Should Retain STERIS (STE) Stock For Now

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Why Is Steris (STE) Down 3.7% Since Last Earnings Report?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Here's Why You Should Hold on to STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Is Steris a Warren Buffett Stock?

Is it the Wrigley's gum of healthcare?

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Steris (STE) Surpasses Q3 Earnings Estimates

Steris (STE) delivered earnings and revenue surprises of 8.72% and 0.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

STERIS Announces Financial Results for Fiscal 2022 Third Quarter

DUBLIN, IRELAND, Feb. 08, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 third quarter ended December 31, 2021. Revenue...

STERIS to Host a Conference Call for Fiscal 2022 Third Quarter Financial Results on February 9, 2022

DUBLIN, IRELAND, Jan. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 third quarter financi...

Steris (STE) Earnings Expected to Grow: Should You Buy?

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evoqua Water Technologies Closes Acquisition of Renal Business from STERIS

PITTSBURGH--(BUSINESS WIRE)--Evoqua Water Technologies Closes Acquisition of Renal Business from STERIS

Other symbols: AQUA

Steris (STE) Upgraded to Buy: Here's Why

Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment

The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.

Evoqua Water To Acquire Steris' Renal Business For $196.3M

Evoqua Water Technologies Corp (NYSE: AQUA) has agreed to acquire the assets of the renal business of Steris PLC (NYSE: STE) for $196.3 million. The acquired renal business, historically operated by Ste...